November 29, 2012
It's official: Abbott Laboratories' (NYSE: ABT ) board of directors has approved the company's spinoff of its pharmaceuticals division to form the new company, AbbVie. The approval was expected, of course, but the announcement has given investors some much-awaited details regarding how AbbVie shares will be distributed among current shareholders. In this video, Motley Fool health care analyst Brenton Flynn tells us what the distribution will be, when it's going to take place, and when to make sure you either buy Abbott or sell -- if you'd like to be a part of the transition or avoid it altogether. Also, he discusses what we can expect the stock to do when the first of the year comes -- and why it will be nothing to worry about.
With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.